Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Hinova Pharmaceuticals (SHSE:688302) Forward PE Ratio Explanation
The Forward PE Ratio of a company is often used to compare current earnings to estimated future earnings, as well as gaining a clearer picture of what earnings will look like without charges and other accounting adjustments. If earnings are expected to grow in the future, the Forward PE Ratio will be lower than the current PE Ratio. This measure is also used to compare one company to another with a forward-looking focus.
Trailing PE Ratio relies on what is already done. It uses the current share price and divides by the total EPS (Basic) over the past 12 months. PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio .
Hinova Pharmaceuticals Forward PE Ratio Related Terms
Hinova Pharmaceuticals Forward PE Ratio Historical Data
* Premium members only.
The historical data trend for Hinova Pharmaceuticals's Forward PE Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Hinova Pharmaceuticals Forward PE Ratio Chart
Hinova Pharmaceuticals Annual Data
Trend
2024-12
Forward PE Ratio
35.55
Hinova Pharmaceuticals Quarterly Data
2024-12
2025-03
Forward PE Ratio
35.55
41.12
SHSE:688302 vs VRTX, REGN, RVMD: Forward PE Ratio Comparison
For the Biotechnology subindustry, Hinova Pharmaceuticals's Forward PE Ratio, along with its competitors' market caps and Forward PE Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Hinova Pharmaceuticals Forward PE Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Hinova Pharmaceuticals's Forward PE Ratio distribution charts can be found below:
* The bar in red indicates where Hinova Pharmaceuticals's Forward PE Ratio falls into.
Hinova Pharmaceuticals Forward PE Ratio Calculation
It's a measure of the price-to-earnings ratio (PE Ratio) using forecasted earnings for the calculation. While the earnings used are just an estimate and are not as reliable as current earnings data, there is still benefit in estimated P/E analysis. The forecasted earnings used in the formula can either be for the next 12 months or for the next full-year fiscal period.
Hinova Pharmaceuticals (SHSE:688302) has a Forward PE Ratio of 40.33 as of Aug. 26, 2026. Forward P/E ratio is the share price dividend by the expected per-share earnings in the next 12 months. View historical data on Hinova Pharmaceuticals and its competitors. According to the industry distribution chart, Hinova Pharmaceuticals ranks #236 out of 357 companies in the Biotechnology industry, placing it in the top 66.1%.
Is Hinova Pharmaceuticals' Forward PE Ratio too high?
Hinova Pharmaceuticals' current Forward PE Ratio is 40.33. The Biotechnology industry median Forward PE Ratio is 23.69. Hinova Pharmaceuticals' value of 40.33 is 70.2% above this industry median. Based on the distribution chart, Hinova Pharmaceuticals ranks #236 out of 357 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Hinova Pharmaceuticals has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.
How does Hinova Pharmaceuticals' Forward PE Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Hinova Pharmaceuticals ranks #236 out of 357 companies for Forward PE Ratio. This places Hinova Pharmaceuticals in the lower half of its industry. The industry median Forward PE Ratio is 23.69. Hinova Pharmaceuticals' value of 40.33 is 70.2% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Forward PE Ratio for a Biotechnology company?
The median Forward PE Ratio among Biotechnology companies is 23.69, based on 357 companies in the industry. Companies in the top quartile (top 25%) have a Forward PE Ratio significantly above this median, while those in the bottom quartile fall well below. However, Forward PE Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Hinova Pharmaceuticals's current Forward PE Ratio of 40.33 is 70.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Forward PE Ratio mean?
A high Forward PE Ratio can signal that a stock is expensive relative to its fundamentals. Forward P/E ratio is the share price dividend by the expected per-share earnings in the next 12 months. View historical data on Hinova Pharmaceuticals and its competitors. For the Biotechnology industry, the median Forward PE Ratio is 23.69 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Hinova Pharmaceuticals's current Forward PE Ratio is 40.33. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hinova Pharmaceuticals stock overvalued right now?
Hinova Pharmaceuticals (SHSE:688302) has a current Forward PE Ratio of 40.33. The current Forward PE Ratio is 40.33 and 70.2% above the Biotechnology industry median of 23.69. Hinova Pharmaceuticals' overall GF Score™ is 32/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Forward PE Ratio calculated?
Forward PE Ratio is calculated from a company's financial statements. For Hinova Pharmaceuticals (SHSE:688302), the current Forward PE Ratio is 40.33 as of Aug. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Hinova Pharmaceuticals Inc is an international drug company based on technology platforms such as deuterium and PROTAC, aiming to develop Best-in-class and First-in-class drugs with major clinical needs. The company focuses on the research and development of drugs in therapeutic areas such as oncology and metabolic diseases, focusing on providing safe, effective and affordable drugs for patients, and is committed to the development and production of drugs with global rights and interests.
32GF Score
Get the complete analysis for SHSE:688302
Forward PE Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:688302 has been successfully added to your 
